News
The president of the Malta Medical Association (MHRA) has publicly called on the Maltese government to reconsider what he described as a serious misstep in the country's cannabis policy direction — a rare instance of the island's organised medical profession taking an explicit public stance on adult-use cannabis regulation since the passage of Malta's 2021 cannabis reform.
The remarks, reported by Times of Malta, did not specify a single legislative clause for repeal but signalled broader unease within parts of the medical establishment about how adult-use cannabis has been implemented under Chapter 628 of the Laws of Malta — the legal architecture that underpins Malta's Cannabis Harm Reduction Association (CHRA) framework and the work of ARUC (Authority on the Responsible Use of Cannabis), the statutory body responsible for licensing and oversight of adult-use cannabis in Malta.
What the Criticism Is — and Is Not
It is worth being precise about what the MHRA president's comments represent. This is a call from a professional medical body for government review, not a clinical finding, not a peer-reviewed outcome study, and not a formal regulatory complaint to ARUC. Medical associations in democratic systems routinely advocate on public health grounds, and their positions carry weight — but they are one voice among several legitimate stakeholders in any cannabis policy conversation.
The MHRA has historically been cautious about cannabis liberalisation, a position it shares with medical bodies in several EU member states where adult-use frameworks are still emerging. That caution is not without basis: genuine clinical questions remain about cannabis use in adolescents, among people with certain psychiatric histories, and in relation to high-potency products. These are areas where the evidence base continues to develop, and where harm reduction frameworks like Malta's CHRA model are specifically designed to provide safeguards.
However, characterising the entire framework as a "big mistake" — without distinguishing between the harm reduction intent of the law and specific implementation gaps — risks conflating two separate questions: whether a regulated adult-use framework is preferable to prohibition, and whether this particular framework is being executed well.
The CHRA Model and Its Harm Reduction Rationale
Malta's approach under Chapter 628 is, by design, a harm reduction framework — not a commercial cannabis market. CHRAs are non-profit, membership-based associations operating under a strict regulatory framework. As detailed in our CHRA regulations guide, licensed associations are subject to ARUC directives covering everything from product testing and THC limits to security requirements, packaging standards, and restrictions on proximity to schools and sensitive locations.
The framework was constructed precisely to address the kind of public health concerns that medical bodies raise — keeping cannabis away from minors, ensuring product safety, and reducing the harms associated with an unregulated black market. Whether those mechanisms are functioning as intended is a legitimate subject for review. Whether the framework itself was a mistake is a much larger claim that requires a higher evidentiary threshold.
Perspectives From Across the Stakeholder Landscape
ARUC has not publicly responded to the MHRA president's comments at the time of publication. The authority has, in the past, described its mandate as evidence-led and adaptive, with the capacity to update directives as the local evidence base matures.
Within Malta's CHRA community, operators have long argued that the framework's non-commercial, association-based structure represents a meaningful public health improvement over prohibition — and that responsible, regulated supply is preferable to an uncontrolled black market in which product safety cannot be guaranteed. That argument has support in the academic harm reduction literature and in the policy positions of organisations such as the European Monitoring Centre for Drugs and Drug Addiction, now operating as the European Union Drugs Agency (EUDA).
Healthcare professionals working in addiction medicine and general practice occupy a more nuanced position. Several, speaking in general terms in past public forums, have acknowledged that regulated access may reduce some harms while raising questions about whether awareness campaigns, patient education, and integration with primary care have kept pace with the legislative change.
What Should Happen Next
If the MHRA's intervention prompts a structured, evidence-led review of Chapter 628's implementation — involving ARUC, the CHRAs, the medical community, and patient advocates — that would be a constructive outcome. Malta's cannabis framework is still relatively young, and no regulated system emerges fully formed. Iteration based on real-world data is how responsible regulation works.
What would be less constructive is a policy reversal driven by institutional discomfort rather than outcome data, or a return to conditions under which Maltese adults who choose to consume cannabis have no legal, regulated, harm-reduced option for doing so.
The medical profession's voice matters in this conversation. So do the voices of adult consumers, CHRA members, harm reduction advocates, and the regulator itself. A credible policy review would include all of them.
The MHRA president's intervention puts cannabis policy back in the Maltese public conversation at a moment when several European governments are watching Malta's model closely. How the government responds — and whether it commissions a proper evidence review or simply absorbs the political pressure — will say a great deal about the maturity of the island's approach to evidence-based drug policy.
Sources
Times of Malta
Featured image: Photo by Efrem Efre on Pexels
Members Discussion